⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7453571 | 1.00 | — | — | |
| SCHEMBL1301420 | 0.69 | TRPA1 (0.53) | — | |
| SCHEMBL1301418 | 0.69 | TRPA1 (0.53) | — | |
| SCHEMBL11317956 | 0.67 | — | — | |
| SCHEMBL4018651 | 0.67 | — | — | |
| SCHEMBL22809171 | 0.65 | — | — | |
| SCHEMBL7458950 | 0.64 | — | — | |
| SCHEMBL19134431 | 0.64 | — | — | |
| SCHEMBL20589982 | 0.64 | — | — | |
| Pentenal SCHEMBL280610 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4519265-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-03-12 | — | — | EP | claimed |
| WO-2023213882-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | WO | claimed |
| EP-4519265-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-03-12 | — | — | EP | disclosed |
| US-20240317721-A1 | PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN | NOVARTIS AG (CH) | 2024-09-26 | — | — | US | disclosed |
| CN-115244055-B | Pyrimidine five-membered ring derivative and application thereof | 江苏先声药业有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-20240208957-A1 | TRIAZINE DERIVATIVE AS REVERSIBLE AND IRREVERSIBLE COVALENT INHIBITORS OF PI3K | UNIVERSITÄT BASEL (CH) | 2024-06-27 | — | — | US | disclosed |
| CN-118084870-A | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084866-A | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084868-A | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084867-A | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-112105419-B | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2023213882-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | WO | disclosed |
| CN-115244055-A | Pyrimido five-membered ring derivative and application thereof | 江苏先声药业有限公司 | 2022-10-25 | — | — | CN | disclosed |
| US-9505765-B2 | 4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as TAK1 inhibitors in disease treatment | CONFLUENCE LIFE SCIENCES INC. (US) | 2016-11-29 | — | — | US | disclosed |
| CN-105566089-A | METHOD FOR PREPARING 3-TRIFLUOROMETHYL CHALCONES | DU PONT | 2016-05-11 | — | — | CN | disclosed |
| US-20150203499-A1 | 4-ALKOXY/ARALKOXY-5-SUBSTITUTED-PYRROLOPYRIMIDINE COMPOUNDS AS TAK1 INHIBITORS IN DISEASE TREATMENT | ACLARIS THERAPEUTICS, INC. | 2015-07-23 | — | — | US | disclosed |
| WO-2014018888-A1 | 4-ALKOXY/ARALKOXY-5-SUBSTITUTED-PYRROLOPYRIMIDINE COMPOUNDS AS TAK1 INHIBITORS IN DISEASE TREATMENT | CONFLUENCE LIFE SCIENCES INC. (US) | 2014-01-30 | — | — | WO | disclosed |
| EP-0890663-B1 | Improved regenerated collagen fiber and method of manufacturing the same | KANEKA CORP (JP) | 2002-11-13 | — | — | EP | disclosed |
| US-6160096-A | Regenerated collagen fiber and method of manufacturing the same | KANEKA CORPORATION (JP) | 2000-12-12 | — | — | US | disclosed |
| EP-0890663-A2 | Improved regenerated collagen fiber and method of manufacturing the same | Kaneka Corporation (JP) | 1999-01-13 | — | — | EP | disclosed |